The number of people using injectable obesity treatments is increasing rapidly, and it is leading to declines in obesity, according to a new survey by the Gallup National Health and Well-Being Index.

The obesity rate dropped to 37% of U.S. adults this year, down from a high of 39.9% three years ago, according to the survey.

The survey found that the number of Americans taking drugs like semaglutide (which include the brands Ozempic and Wegovy) or tirzepatide (under the brands Zepbound and Mounjaro) for weight loss more than doubled over the past year and a half. That's 12.4% of respondents taking the drugs compared with 5.8% in February 2024, when Gallup first measured it. GLP-1 agonists, as the new treatments are known, were first approved in the U.S. market in 2021.

GLP-1s, which act

See Full Page